High density lipoprotein landmark trials: Difference between revisions
Jump to navigation
Jump to search
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
| Line 25: | Line 25: | ||
| [[ACCELERATE Trial]] | | [[ACCELERATE Trial]] | ||
|- | |- | ||
| [[ | | [[Dal-OUTCOMES Trial]] | ||
|- | |- | ||
| [[DEFINE Trial]] | | [[DEFINE Trial]] | ||
|- | |||
| [[Dal-VESSEL Trial]] | |||
|- | |||
| [[Dal-PLAQUE]] | |||
|- | |- | ||
| [[ILLUMINATE Trial]] | | [[ILLUMINATE Trial]] | ||
Revision as of 01:21, 20 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
High density lipoprotein landmark trials On the Web |
|
American Roentgen Ray Society Images of High density lipoprotein landmark trials |
|
Risk calculators and risk factors for High density lipoprotein landmark trials |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Reconstituted HDL Infusion
CETP Inhibitors
| ACCELERATE Trial |
| Dal-OUTCOMES Trial |
| DEFINE Trial |
| Dal-VESSEL Trial |
| Dal-PLAQUE |
| ILLUMINATE Trial |
| ILLUSTRATE Trial |
| REVEAL Trial |
Niacin
| AIM-HIGH Trial |
| ARBITER 2 Trial |
| ARBITER 3 Trial |
| ARBITER 6-HALTS Trial |
| CLAS Trial |
| HATS Trial |
| Oxford Niaspan Study |
Fibrate
| VA-HIT Trial |
| BECAIT Trial |
| BIP Trial |
Statin
| ASTEROID Trial |
| SATURN Trial |
| 4S Trial |
| CORONA Trial |
Multiple Lipid Lowering Drugs
| HARP Study |
| AFREGS Trial |